Physician profile
Leonard Kaplan
NPI 1982653697
$2,606.69
in general payments reported to CMS, 2019-2025
25 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $349 · 2021: $376 · 2022: $611 · 2023: $344 · 2024: $133 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $679.19 | 2021-2024 | Senza |
| Allergan, INC. | $353.90 | 2019-2022 | |
| Abbvie INC. | $345.09 | 2022-2023 | |
| Globus Medical, INC. | $255.29 | 2025 | Senza, Vyrsa V1, Omnia |
| Abbott Laboratories | $131.44 | 2019-2022 | |
| Galderma Laboratories, L.P. | $112.97 | 2019 | |
| Sentynl Therapeutics, INC. | $83.47 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $72.36 | 2020 | |
| Livanova USA, INC. | $69.79 | 2021-2022 | |
| Daiichi Sankyo INC. | $52.19 | 2019 | |
| Mdd US Operations, LLC | $51.10 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $48.95 | 2019 | |
| Assertio Therapeutics, INC. | $47.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $43.28 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $36.88 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.96 | 2019-2020 | |
| Pfizer INC. | $32.91 | 2019 | |
| Scilex Pharmaceuticals INC. | $27.90 | 2019-2021 | |
| Astellas Pharma US INC | $26.22 | 2024 | Veozah |
| Shionogi INC | $22.17 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.97 | 2024 | Rebyota |
| Supernus Pharmaceuticals, INC. | $16.61 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.47 | 2021 | |
| Ge Healthcare | $14.34 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.